摘要
目的 探讨异基因造血干细胞移植 (Allo HSCT)治疗白血病的疗效、造血重建及生存情况。方法 白血病患者 10例 ,其中同胞间HLA相合的异基因外周血干细胞移植 (Allo PBSCT)7例 ,无亲缘关系HLA不全相合脐血移植 (UCBT) 3例。结果 9/10例受者获造血重建 ,UCBT患者造血重建速度较HLA相合的同胞PBSCT慢 ,1例UCBT移植后 35天造血未重建 ,回输自体外周血干细胞后 ,仍未能重建造血 ,于 72天死亡。其余至今均无病生存。结论 Allo HSCT是目前治愈白血病的有效方法 ,对于无同胞HLA相合的供者 ,选择细胞数量较高、HLA 1～ 2个位点不合的UCBT仍然有效可行。
Objective To investigate the effect and hematopoietic reconstitution as well as survival of allogeneic hematopoietic stem cell transplantation(Allo-HSCT)in the treatment of leukemia.Methods Seven patients with leukemia received Allo-PBSCT from HLA matched sibling donors.Three patients received HLA-mismatched unrelated umbilical cord blood transplantation.Results Nine recipients acheived hematopoietic reconstitution.The median time of hematopoietic reconstitution after UCBT was longer than that of HLA matched sibling PBSCT.one patient died of graft failure on the 72th day post UCBT.Conclusion Allo-HSCT is effective for the cure of patients with leukemia.UCBT with enough cells and 1 mismatched loci is safe and effective for the patients who had no HLA matched sibling donors.
出处
《癌症进展》
2005年第2期102-105,共4页
Oncology Progress
关键词
白血病
异基因
造血干细胞移植
leukemia hematopoietic stem cell transplantation allogeneic
